Hepatitis C Virus Envelope Glycoprotein E2 Glycans Modulate Entry, CD81 Binding, and Neutralization

ABSTRACT Hepatitis C virus (HCV) is a major human pathogen that causes serious liver disease, including cirrhosis and hepatocellular carcinoma. The primary target cells of HCV are hepatocytes, and entry is restricted by interactions of the envelope glycoproteins, E1 and E2, with cellular receptors. E1 and E2 form noncovalently linked heterodimers and are heavily glycosylated. Glycans contribute to protein folding and transport as well as protein function. In addition, glycans associated with viral envelopes mask important functional domains from the immune system and attenuate viral immunogenicity. Here, we explored the role of N- and O-linked glycans on E2, which is the receptor binding subunit of the HCV envelope. We identified a number of glycans that are critical for viral entry. Importantly, we showed that the removal of several glycans significantly increased the inhibition of entry by sera from HCV-positive individuals. Only some of the glycans that affected entry and neutralization were also important for CD81 binding. Our results show that HCV envelope-associated glycans play a crucial role in masking functionally important regions of E2 and suggest a new strategy for eliciting highly neutralizing antibodies against this virus.

[1]  D. Lavillette,et al.  Characterization of host‐range and cell entry properties of the major genotypes and subtypes of hepatitis C virus , 2005, Hepatology.

[2]  Charles M. Rice,et al.  Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry , 2007, Nature.

[3]  T. Dragic,et al.  CD81 is an entry coreceptor for hepatitis C virus. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[4]  M. Houghton,et al.  A quantitative test to estimate neutralizing antibodies to the hepatitis C virus: cytofluorimetric assessment of envelope glycoprotein 2 binding to target cells. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[5]  M. Rossmann,et al.  Locations of Carbohydrate Sites on Alphavirus Glycoproteins Show that E1 Forms an Icosahedral Scaffold , 2001, Cell.

[6]  C. Rice,et al.  Neutralizing antibody response during acute and chronic hepatitis C virus infection. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[7]  B. Bartosch,et al.  Infectious Hepatitis C Virus Pseudo-particles Containing Functional E1–E2 Envelope Protein Complexes , 2003, The Journal of experimental medicine.

[8]  G. Deléage,et al.  Conservation of the Conformation and Positive Charges of Hepatitis C Virus E2 Envelope Glycoprotein Hypervariable Region 1 Points to a Role in Cell Attachment , 2001, Journal of Virology.

[9]  Anna Tramontano,et al.  A model for the hepatitis C virus envelope glycoprotein E2 , 2000, Proteins.

[10]  J. Binley,et al.  Variable-Loop-Deleted Variants of the Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Can Be Stabilized by an Intermolecular Disulfide Bond between the gp120 and gp41 Subunits , 2000, Journal of Virology.

[11]  S. Levy,et al.  In search of hepatitis C virus receptor(s). , 2001, Clinics in liver disease.

[12]  M. Clementi,et al.  Cross-reactive pseudovirus-neutralizing anti-envelope antibodies coexist with antibodies devoid of such activity in persistent hepatitis C virus infection. , 2004, Virology.

[13]  Wei Zhang,et al.  Placement of the Structural Proteins in Sindbis Virus , 2002, Journal of Virology.

[14]  J. Dubuisson,et al.  Characterization of Hepatitis C Virus E2 Glycoprotein Interaction with a Putative Cellular Receptor, CD81 , 1999, Journal of Virology.

[15]  J. Dubuisson,et al.  Analysis of the glycosylation sites of hepatitis C virus (HCV) glycoprotein E1 and the influence of E1 glycans on the formation of the HCV glycoprotein complex. , 1999, The Journal of general virology.

[16]  T. Liang,et al.  Structural features of envelope proteins on hepatitis C virus-like particles as determined by anti-envelope monoclonal antibodies and CD81 binding. , 2002, Virology.

[17]  M. Major,et al.  Immunization of chimpanzees with an envelope protein-based vaccine enhances specific humoral and cellular immune responses that delay hepatitis C virus infection. , 2004, Vaccine.

[18]  T. Chambers,et al.  HCV E2 glycoprotein: mutagenesis of N-linked glycosylation sites and its effects on E2 expression and processing. , 2004, Virology.

[19]  Jean Dubuisson,et al.  Cyanovirin-N Inhibits Hepatitis C Virus Entry by Binding to Envelope Protein Glycans* , 2006, Journal of Biological Chemistry.

[20]  Stephen D Fuller,et al.  Low pH induces swiveling of the glycoprotein heterodimers in the Semliki forest virus spike complex , 1995, Cell.

[21]  Paul J Maddon,et al.  L-SIGN (CD 209L) is a liver-specific capture receptor for hepatitis C virus , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[22]  R. Clayton,et al.  Functional analysis of hepatitis C virus E2 glycoproteins and virus-like particles reveals structural dissimilarities between different forms of E2. , 2001, The Journal of general virology.

[23]  N. Kato,et al.  Susceptibility of human T-lymphotropic virus type I infected cell line MT-2 to hepatitis C virus infection. , 1995, Biochemical and biophysical research communications.

[24]  T. Shikata,et al.  Experimental vaccine activities of recombinant E1 and E2 glycoproteins and hypervariable region 1 peptides of hepatitis C virus in chimpanzees , 1999, Archives of Virology.

[25]  J. Pawlotsky Hepatitis C virus infection: virus/host interactions , 1998, Journal of viral hepatitis.

[26]  T. Dragic,et al.  Different Domains of CD81 Mediate Distinct Stages of Hepatitis C Virus Pseudoparticle Entry , 2006, Journal of Virology.

[27]  Bette Korber,et al.  Tracking global patterns of N-linked glycosylation site variation in highly variable viral glycoproteins: HIV, SIV, and HCV envelopes and influenza hemagglutinin. , 2004, Glycobiology.

[28]  W P Havens,et al.  Viral hepatitis. , 1970, The Medical clinics of North America.

[29]  Man-Fung Yuen,et al.  Viral hepatitis B , 2003, The Lancet.

[30]  R. Garry,et al.  Proteomics computational analyses suggest that hepatitis C virus E1 and pestivirus E2 envelope glycoproteins are truncated class II fusion proteins. , 2003, Virology.

[31]  D. Vlahov,et al.  Protection against persistence of hepatitis C , 2002, The Lancet.

[32]  B. Walker,et al.  Analysis of Successful Immune Responses in Persons Infected with Hepatitis C Virus , 2000, The Journal of experimental medicine.

[33]  Charles M. Rice,et al.  Flaviviridae :T he Viruses and Their Replication , 2007 .

[34]  M. Lai,et al.  Establishment of B-Cell Lymphoma Cell Lines Persistently Infected with Hepatitis C Virus In Vivo and In Vitro: the Apoptotic Effects of Virus Infection , 2003, Journal of Virology.

[35]  C. Rice,et al.  CD81 Is Required for Hepatitis C Virus Glycoprotein-Mediated Viral Infection , 2004, Journal of Virology.

[36]  R. Cortese,et al.  Cell Entry of Hepatitis C Virus Requires a Set of Co-receptors That Include the CD81 Tetraspanin and the SR-B1 Scavenger Receptor* , 2003, Journal of Biological Chemistry.

[37]  M. Houghton,et al.  Binding of hepatitis C virus to CD81. , 1998, Science.

[38]  E. Schreier,et al.  Antibodies in human sera specific to hypervariable region 1 of hepatitis C virus can block viral attachment. , 1995, Virology.

[39]  R. Doms,et al.  DC-SIGNR, a DC-SIGN homologue expressed in endothelial cells, binds to human and simian immunodeficiency viruses and activates infection in trans , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[40]  A. Maerz,et al.  A Conserved Gly436-Trp-Leu-Ala-Gly-Leu-Phe-Tyr Motif in Hepatitis C Virus Glycoprotein E2 Is a Determinant of CD81 Binding and Viral Entry , 2006, Journal of Virology.

[41]  Martin A. Nowak,et al.  Antibody neutralization and escape by HIV-1 , 2003, Nature.

[42]  T. Katayama Transfusion-associated hepatitis , 1985 .

[43]  O. Schwartz,et al.  DC-SIGN and L-SIGN Are High Affinity Binding Receptors for Hepatitis C Virus Glycoprotein E2* , 2003, Journal of Biological Chemistry.

[44]  S D Fuller,et al.  Molecular organization of a recombinant subviral particle from tick-borne encephalitis virus. , 2001, Molecular cell.

[45]  D. Fry,et al.  Hepatitis: an overview of important issues. , 1997, Bulletin of the American College of Surgeons.

[46]  R. Cortese,et al.  The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus , 2002, The EMBO journal.

[47]  A. Tramontano,et al.  Binding of the Hepatitis C Virus E2 Glycoprotein to CD81 Is Strain Specific and Is Modulated by a Complex Interplay between Hypervariable Regions 1 and 2 , 2003, Journal of Virology.

[48]  W. Olson,et al.  L-SIGN (CD209L) and DC-SIGN (CD209) mediate transinfection of liver cells by hepatitis C virus. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[49]  S. Emerson,et al.  In vitro assay for neutralizing antibody to hepatitis C virus: Evidence for broadly conserved neutralization epitopes , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[50]  R. Purcell,et al.  Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[51]  J. Navaza,et al.  The Fusion Glycoprotein Shell of Semliki Forest Virus An Icosahedral Assembly Primed for Fusogenic Activation at Endosomal pH , 2001, Cell.

[52]  H. Drummer,et al.  Hepatitis C Virus Glycoprotein E2 Contains a Membrane-proximal Heptad Repeat Sequence That Is Essential for E1E2 Glycoprotein Heterodimerization and Viral Entry* , 2004, Journal of Biological Chemistry.

[53]  R. Doms,et al.  Hepatitis C Virus Glycoproteins Interact with DC-SIGN and DC-SIGNR , 2003, Journal of Virology.

[54]  S. Harrison,et al.  The envelope glycoprotein from tick-borne encephalitis virus at 2 Å resolution , 1995, Nature.

[55]  E. Keeffe,et al.  Quantitative analysis of hepatitis C virus in peripheral blood and liver: replication detected only in liver. , 2001, The Journal of infectious diseases.

[56]  J. H. Strauss,et al.  Structure of dengue virus: implications for flavivirus organization, maturation, and fusion , 2002 .

[57]  M. Houghton,et al.  Perspectives for a vaccine against hepatitis C virus. , 1999, Journal of hepatology.

[58]  R. Doms,et al.  Quantitative Expression and Virus Transmission Analysis of DC-SIGN on Monocyte-Derived Dendritic Cells , 2002, Journal of Virology.

[59]  Birke Bartosch,et al.  Role of N-Linked Glycans in the Functions of Hepatitis C Virus Envelope Glycoproteins , 2005, Journal of Virology.

[60]  F. Penin,et al.  Construction and characterization of chimeric hepatitis C virus E2 glycoproteins: analysis of regions critical for glycoprotein aggregation and CD81 binding. , 2000, The Journal of general virology.

[61]  P Parham,et al.  Analysis of a successful immune response against hepatitis C virus. , 1999, Immunity.